Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Summary

This phase II trial studies how well pembrolizumab works in treating patients with B-cell non-Hodgkin lymphoproliferative diseases that have not been treated. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2018-07-09

Primary completion

2021-06-09

Completion

2024-08-29

Outcome

Outcome not reported

Stopped (Enrollment): “Closed per SRC Low Accrual Policy.”

Drugs

Indications